multiple myeloma

39 · 20 / page

Ask MedXY AI

Latest news

Tag

Hematology-OncologyBCMACAR T-cell therapy

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

By MedXY|Oct 14, 2025

Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune ev

Hematology-OncologybiomarkersCD38

multiple myeloma

Latest news

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

Decoding Response-Adapted Daratumumab Therapy in Elderly Multiple Myeloma: Biomarkers and Mechanisms of Sensitivity and Resistance

Real-World Impact of Cilta-cel versus Ide-cel in CAR T-Cell Therapy for Multiple Myeloma: Insights from the German DRST Registry

Circulating Tumor Cells as Prognostic Biomarkers in Transplant-Eligible Multiple Myeloma Patients Undergoing Frontline Quadruplet Therapy

Busulfan-Melphalan Conditioning Enhances Outcomes in Newly Diagnosed Multiple Myeloma with Reinforced VRD: Insights from the Phase 3 GEM12 Trial

Unraveling the Prognostic Impact of Co-Occurring High-Risk Cytogenetic Abnormalities in Multiple Myeloma

Optimizing Therapy in Transplant-Ineligible Multiple Myeloma: Insights from the REST Phase 2 Trial on Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone

Five-Year Outcomes of FCARH143: A Fully Human BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

Clonal Hematopoiesis and Its Link to Severe Cytokine Release Syndrome in CAR T-Cell Therapy Recipients

Modakafusp alfa in Relapsed/Refractory Multiple Myeloma: Insights from a Phase 2 Randomized Dose Optimization Study

Advancements in Long-Term Outcomes for Multiple Myeloma: Insights from Early Total Therapy Protocols

Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial

Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA

Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial

Optimizing Induction Therapy in Older, Fit Patients with Newly Diagnosed Multiple Myeloma: Insights from the GEM-2017FIT Phase 3 Trial

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial

Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial